Faculty Summaries
Vladimir Kolenko
Vladimir Kolenko, MD, PhD
Associate Professor
  • Adjunct Professor, Temple University
Office Phone: 215-728-5620
Fax: 215-728-4333
Office: W246
Research Interests
  • Resistance to multitargeted receptor tyrosine kinase inhibitors (TKIs) in genitourinary tumors
  • Therapeutic potential of piperlongumine and its derivatives
  • Therapeutics of XIAP degradation by zinc chelators
  • The role of zinc in prostate carcinogenesis
Description of research projects
Selected Publications

Fox Chase Programs

  1. Golovine K., Makhov P., Naito S., Raiyani H., Tomaszewski J., Mehrazin R., Tulin A., Kutikov A., Uzzo, R.G., Kolenko, V.M. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biology & Therapy. 16(5):743-9, 2015. PMC Journal – In Process. PubMed
  2. Makhov P., Golovine K., Teper E., Kutikov A., Mehrazin R., Corcoran A., Tulin A., Uzzo R.G., Kolenko V.M. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signaling and mediates cancer cell death. British Journal of Cancer. 110(4):899-907, 2014. PMCID: PMC3929888. PubMed
  3. Ginzburg S., Golovine K., Makhov P., Uzzo R.G., Kutikov A., Kolenko V.M. Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. The Prostate. 74(2):177-86, 2014. PMCID: PMC4052841. PubMed
  4. Kolenko V.M., Teper E., Kutikov A., Uzzo R.G. Zinc and zinc transporters in prostate carcinogenesis. Nature Reviews Urology. 10(4):219-26, 2013. PMCID: PMC3702371. PubMed
  5. Golovine K., Makhov P., Teper E., Kutikov A., Canter D., Uzzo R.G., Kolenko V.M. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. The Prostate. 73(1):23-30, 2013. PMCID: PMC3491117. PubMed
  6. Teper E., Makhov P., Golovine K., Canter D.J., Myers C.B., Kutikov A., Uzzo R.G., Kolenko V.M. The Effect of 5-Aminolevulinic Acid and its Derivatives on Protoporphyrin IX Accumulation and Apoptotic Cell Death in Castrate-Resistant Prostate Cancer Cells. Urology. 80(6):1391.e1-7, 2012. PMCID: PMC3514607. PubMed
  7. Makhov P., Golovine K., Kutikov A., Teper E., Canter D.J., Simhan J., Uzzo R.G., Kolenko V.M. Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells. Mol Cancer Ther. 11(7):1510-7, 2012. PMCID: PMC3491642. PubMed
  8. Makhov P., Golovine K., Canter D.J., Kutikov A., Simhan J., Corlew M.M., Uzzo R.G., Kolenko V. Co-Administration of Piperine and Docetaxel Results in Improved Anti-Tumor Efficacy via Inhibition of CYP3A4 Activity. The Prostate. 72(6):661-7, 2012. PMCID: PMC3208085. PubMed
  9. Makhov P., Golovine K., Kutikov A., Canter D.J., Rybko V., Roshchin D., Matveev V., Uzzo R.G., Kolenko V. Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis. 32(12):1773-81, 2011. PMCID: PMC3220607. PubMed
  10. Kutikov A., Makhov P., Golovine K., Canter D.J., Mohit S., Street R., Simhan J., Uzzo R.G., Kolenko V. Interleukin-6: A Potential Biomarker of Resistance to Multitargeted Receptor Tyrosine Kinase Inhibitors in Castration-Resistant Prostate Cancer. Urology. 78(4):968.e7-968.e11, 2011. PMCID: PMC3190126. PubMed
  11. Canter D.J., Kutikov A., Golovine K., Makhov P., Simhan J., Uzzo R.G., Kolenko V. Are All Multi-targeted Tyrosine Kinase Inhibitors Created Equal? An In Vitro Study of Sunitinib and Pazopanib in Renal Cell Carcinoma Cell Lines. The Canadian Journal of Urology. 18(4):5819-25, 2011. PMCID: PMC3182114. PubMed
  12. Makhov, P., Kutikov, A., Golovine, K., Uzzo, R.G., Canter, D.J., Kolenko, V. Docetaxel-mediated Apoptosis in Myeloid Progenitor TF-1 Cells is Mitigated by Zinc: Potential Implication for Prostate Cancer Therapy. The Prostate. 71(13):1413-9, 2011.
  13. Golovine, K., Makhov, P., Uzzo, RG., Kutikov, A., Kaplan, DJ, Fox, E., Kolenko, V. Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-kappaB-independent, proteasome-mediated mechanism. Molecular Cancer. 9:183, 2010. PubMed
All publications